Molecular Profile |
Indication/Tumor Type |
Response Type |
Relevant Treatment Approaches |
Therapy Name |
Approval Status |
Evidence Type |
Efficacy Evidence |
References |
RB1 loss
|
lung small cell carcinoma
|
resistant |
|
Trilaciclib
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, RB1-deficient small cell lung cancer cell lines were resistant to Trilaciclib (G1T28) in culture and in xenograft models (PMID: 26826116).
|
26826116
|
RB1 loss
|
lung small cell carcinoma
|
sensitive |
|
Trilaciclib + Topotecan
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, the combination of Trilaciclib (G1T28) and Hycamtin (topotecan) inhibited tumor growth in RB1-deficient small cell lung cancer cell line xenograft models, with greater efficacy than Hycamtin (topotecan) alone (PMID: 26826116).
|
26826116
|
RB1 loss
|
retinoblastoma
|
sensitive |
HDAC Inhibitor
|
Trichostatin A
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Trichostatin A (TSA) inhibited growth of retinoblastoma cell lines in culture (PMID: 18483379), which have been demonstrated to be deficient in RB1 (PMID: 23498719).
|
23498719
18483379
|
RB1 loss
|
estrogen-receptor positive breast cancer
|
resistant |
|
Palbociclib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, RB1 loss was associated with acquired resistance to Ibrance (palbociclib) in an estrogen-receptor positive breast cancer cell line in culture (PMID: 27020857).
|
27020857
|
RB1 loss
|
Advanced Solid Tumor
|
no benefit |
|
Palbociclib
|
Preclinical |
Actionable |
In preclinical studies, the CDK4/6 inhibitor, Ibrance (palbociclib), was not effective in a variety of solid tumors with Rb1-deficiency (PMID: 26649278).
|
26649278
|
RB1 loss
|
retinoblastoma
|
sensitive |
|
Sirolimus
|
Preclinical |
Actionable |
In a preclinical study, Sirolimus (rapamycin) decreased tumor occurrence, tumor hypoxia and tumor vascularization in a retinoblastoma mouse model with functionally inactivated Rb protein (PMID: 21468343, PMID: 1689463).
|
21468343
1689463
|
RB1 loss
|
retinoblastoma
|
sensitive |
HDAC Inhibitor
|
Vorinostat
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Zolinza (vorinostat) inhibited growth of retinoblastoma cell lines in culture (PMID: 18483379), which have been demonstrated to be deficient in RB1 (PMID: 23498719).
|
23498719
18483379
|
RB1 loss
|
neuroendocrine tumor
|
sensitive |
|
Sirolimus
|
Preclinical |
Actionable |
In a preclinical study, Sirolimus (rapamycin) slowed pituitary tumors and decreased the occurrence of thyroid tumors in Rb1+/- mice (PMID: 23454836).
|
23454836
|
RB1 loss
|
retinoblastoma
|
sensitive |
HDAC Inhibitor
|
Entinostat
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, Entinostat (MS-275) inhibited growth of retinoblastoma cell lines in culture and inhibited tumor growth in a retinoblastoma cell line xenograft model (PMID: 18483379), which have been demonstrated to be deficient in RB1 (PMID: 23498719).
|
23498719
18483379
|